MULTIPLE MYELOMA, REFRACTORY

This study tests whether adding the drug selinexor to standard bispecific antibody therapy can help people with multiple myeloma that has come back or stopped responding to other treatments. About 27 adults will receive the combination for up to 12 months. The main goals are to c…

This study tests a drug called selinexor combined with low-dose dexamethasone (and sometimes bortezomib) in people with multiple myeloma that has stopped responding to many other treatments. The goal is to see if these combinations can shrink tumors and control the disease. About…

This early study tests a new treatment called BCMA-UCART for adults with multiple myeloma that has come back or not responded to other therapies. The treatment uses donor immune cells that are specially designed to find and attack cancer cells. The goal is to see if it is safe an…

This study tests a new drug called inobrodib combined with two standard medicines (pomalidomide and dexamethasone) in 100 adults whose multiple myeloma has come back or no longer responds to available therapies. The goal is to see how well the combination shrinks or controls the …

This study looks at multiple myeloma patients who are receiving a newer kind of immunotherapy called a BCMA-directed T cell engager. These treatments can weaken the immune system and raise the risk of serious infections. The trial will compare two target levels of immunoglobulin …

This study tests a treatment called anti-BCMA CAR-T cell therapy for adults with multiple myeloma that has come back or stopped responding to other treatments. The therapy uses a patient's own immune cells, modified in a lab to better find and attack cancer cells. The goal is to …

This study looks at whether adding early palliative care to usual treatment helps people with multiple myeloma or aggressive lymphoma feel better. About 144 patients and their caregivers will either get early palliative care or standard care alone. Researchers will track quality …